Don't want emails from us anymore? Click here to unsubscribe.
Hello!
New Alert: NanoViricides, Inc. (NYSE American: NNVC)
NNVC is our new NYSE high volatility alert with a bounce opportunity.
NNVC has a history of experiencing significant volatility in a short period of time.
NNVC could be presenting a unique opportunity where it has significantly deviated from its 50 day moving average.
While an increased gap does not suggest that it will get smaller, it does create the opportunity for upside potential.
NNVC has a 50 day moving average of 1.40, more than 25% above yesterday's close.
In addition, NNVC has a RSI of 29, suggesting the potential for increased upside.
In the event that NNVC holds above its lows from yesterday, it could present a bounce higher.
NNVC is a NYSE listed "clinical stage company that is creating special purpose nanomaterials for antiviral therapy".
The Company's "novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc".
The Company has a "Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments."
NNVC's "lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections".
"The Company is currently focused on advancing NV-387 into Phase II human clinical trials."
In addition, the company's "other advanced drug candidate is NV-HHV-1 for the treatment of Shingles".
As the company explained in its most recent press release last week:
- "The Phase II-ready drug NV-387 has demonstrated extremely broad antiviral spectrum of activity in animal models, which could prove to be as revolutionary for viral infections as penicillin was for bacterial infections. This broad spectrum is because NV-387 is designed to mimic a host-side feature that is used by over 90-95% of human pathogenic viruses when they cause infection."
Furthermore:
- "In addition, the Company has developed a platform that enables important non-oral drugs to be delivered as active oral drugs, which we believe is a sought after technology by Pharma companies."
In November, the company announced:
"NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID"
Here are a few of the highlights from this press release:
- "We have made significant progress in the regulatory advancement of NV-387. A Phase Ia/Ib clinical trial in healthy subjects was completed with all subjects discharged as of end of December, 2023. There were no adverse events reported. We are now awaiting a final report of this Phase I clinical trial."
- "Additionally, we have made significant progress towards initiating Phase II clinical trial of NV-387 for the treatment of MPox infection in Central Africa. The MPox Clade 1/1b infection has been declared a Public Health Emergency of International Concern (PHEIC) by the WHO. Spillover cases have occurred in several Eastern and Western countries already, raising the probability that the epidemic may spread more widely, although the current MPox virus is not as communicable as coronaviruses. The MPox Clade 1/1b has a substantially greater fatality rate than COVID, at 3-4%, and it has been disproportionately affecting pediatric populations."
- "There is currently no drug available for the treatment of MPox infection. A drug approved for Smallpox/Mpox and stockpiled by the US Strategic National Stockpile, namely tecovirimat (TPOXX®, SIGA), was found to be ineffective for the treatment of the MPox infection in a clinical trial co-sponsored by NIH/NIAID. A vaccine developed for Smallpox, Jynneos (Bavarian Nordic) is being deployed but is in short supply. Its clinical utility for MPox Clade 1/1b is not known."
The company has announced several developments recently.
In December, the company announced:
"NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape"
As the company further explained in this press release:
"Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."
In addition, most recently, the company announced:
- "Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals"
Make sure to do your own due diligence.
Sources: PR1, PR2, PR3, PR4, Website, Chart
Happy Trading!
UltimateStockAlerts
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
